Prophylactic use of fluconazole in neutropenic cancer patients. Issue 835 (May 1995)

• Record Type: Journal Article
• Authors: Yamaç, K.; Senol, E.; Haznedar, R.
• Is Part Of: Postgraduate medical journal. Volume 71:Issue 835(1995)
• Page Start: 284
• Page End: 286
• Publication Date: 1995-05
• Subjects: Medicine -- Periodicals; 610
• DOI: 10.1136/pgmj.71.835.284
• Languages: English
• ISSNs: 0032-5473

Abstract

Abstract : This study was carried out on 70 patients with haematological or solid malignancies who were receiving chemotherapy and/or radiotherapy. Forty-one patients were randomly assigned to receive fluconazole, 400 mg/day, while they were neutropenic. Systemic fungal infection developed in four of the 41 patients (9%) receiving prophylaxis in comparison to nine of 29 patients (31%) not receiving prophylaxis. The incidence of systemic fungal infection was significantly different between the groups receiving prophylaxis and those not receiving it (p < 0.05). Fluconazole was found to be effective for preventing systemic fungal infections in neutropenic patients with cancer.